Clinical Manual for Management of the HIV-Infected ... - myCME.com

More documents

Recommendations

Info

References ♦ ♦ ♦ ♦ Dieterich DT, Poles MA, Cappell MS, et al. Gastrointestinial Manifestations of HIV Disease, Including the Peritoneum and Mesentery. In: Merigan TC, Bartlett JG, Bolognesi D, eds. Textbook of AIDS Medicine, 2nd ed. Baltimore: Williams & Wilkins; 1999:542-6. Sande MA, Eliopoulos GM, Moellering RC, et al. The Sanford Guide to HIV/AIDS Therapy, 14th ed. Hyde Park, VT: Antimicrobial Therapy, Inc.; 2005. Uphold CR, Graham MV. Clinical Guidelines in Adult Health, 2nd ed. Gainesville, FL: Barmarrae Books; 1999. Wilcox CM, Monkemuller KE. Gastrointestinal Disease. In: Dolin R, Masur H, Saag MS, eds. AIDS Therapy. New York: Churchill Livingstone;1999:752- 56. Section 5—Complaint-Specific Workups | 5–15
Page 1 and 2:
Clinical Manual for Management of t
Page 3 and 4:
Table of Contents Clinical Manual f
Page 5 and 6:
Clinical Manual for Management of t
Page 7 and 8:
Preface—About this Manual | Clini
Page 9:
Previous Editions Atlanta Contribut
Page 12 and 13:
♦ ♦ ♦ ♦ ♦ | Clinical Manu
Page 14 and 15:
1-2 | Clinical Manual for Managemen
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
Page 23 and 24:
Initial Physical Examination Backgr
Page 25 and 26:
Genitals/Rectum • Inspect the gen
Page 27 and 28:
Initial and Interim Laboratory and
Page 29 and 30:
Section 1—Testing and Assessment
Page 31:
Patient Education ♦ ♦ ♦ ♦ D
Page 34 and 35:
1-22 | Clinical Manual for Manageme
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 51 and 52:
Section 2—Health Maintenance and
Page 53:
References ♦ ♦ ♦ ♦ ♦ ♦
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 67 and 68:
Occupational Postexposure Prophylax
Page 69 and 70:
P: Plan Laboratory Testing Provide
Page 71 and 72:
For hepatitis C, no recommended pro
Page 73 and 74:
Page 75 and 76:
as hepatitis C or another sexually
Page 77 and 78:
for treatment is appropriate, and b
Page 79 and 80:
Page 81 and 82:
contact with the patient. Patients
Page 83 and 84:
tablet daily of trimethoprim-sulfam
Page 85 and 86:
Opportunistic Infection Prophylaxis
Page 87 and 88:
Discontinuing Primary Prophylaxis P
Page 89 and 90:
Latent Tuberculosis Background Late
Page 91 and 92:
INH may cause liver toxicity and it
Page 93:
Patient Education ♦ ♦ ♦ ♦
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 117 and 118:
Reducing Maternal-Infant HIV Transm
Page 119 and 120:
Some states require written informe
Page 121 and 122:
contraindicated during pregnancy be
Page 123 and 124:
Section 3—Antiretroviral Therapy
Page 125 and 126:
Nelfinavir (Viracept) Adequate drug
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133:
♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151: 4-2 | Clinical Manual for Managemen
Page 158 and 159: 4-10 | Clinical Manual for Manageme
Page 165 and 166: Section 4—Complications of Antire
Page 167 and 168: ♦ ♦ ♦ Toronto General Hospita
Page 169 and 170: Adverse Reactions to HIV Medication
Page 171 and 172: ♦ ♦ ♦ ♦ ♦ Vital signs: No
Page 173 and 174: egimen, symptoms of fatigue could i
Page 175 and 176: Recreational Drugs and Antiretrovir
Page 177 and 178: Section 4—Complications of Antire
Page 179 and 180: LSD, Mescaline, Psilocin, and Methy
Page 181 and 182: Immune Reconstitution Syndrome Back
Page 183 and 184: A: Assessment In the appropriate cl
Page 185 and 186: ♦ ♦ ♦ ♦ ♦ Navas E, Martin
Page 199: 5-14 | Clinical Manual for Manageme
Page 206 and 207: Fatigue Background Fatigue is defin
Page 208: Patient Education ♦ ♦ ♦ ♦
Page 218 and 219: Nausea and Vomiting Background Naus
Page 220: ♦ ♦ ♦ Lorazepam (Ativan) may
Page 230 and 231: Vaginitis/Vaginosis Background Vagi
Page 232 and 233: Treatment: Alternative regimens ♦
Page 234 and 235: Anal Dysplasia Background Anal canc
Page 236: Patient Education ♦ ♦ ♦ Women
Page 242 and 243: Candidiasis, Vulvovaginal Backgroun
Page 244: Patient Education ♦ ♦ ♦ ♦
Page 250 and 251:
Cryptococcal Disease Background Cry
Page 252:
up to 30 mL of CSF to lower the ICP
Page 255 and 256:
Page 258 and 259:
Cytomegalovirus Disease Background
Page 260 and 261:
CMV retinitis Treatment consists of
Page 262 and 263:
Dermatologic Staphylococcal Infecti
Page 264:
Known or suspected MSSA SSTI Treat
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 282 and 283:
Herpes Zoster/Shingles Background S
Page 284 and 285:
Histoplasmosis Background Histoplas
Page 286:
Patient Education ♦ ♦ ♦ ♦ H
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 308 and 309:
Section 6—Disease-Specific Treatm
Page 310 and 311:
Table 1. World Health Organization
Page 312:
Table 3. Monitoring for Toxicity Si
Page 315 and 316:
Page 318 and 319:
Pelvic Inflammatory Disease Backgro
Page 320 and 321:
Table 1. Treatment Regimens for Pel
Page 322 and 323:
Pneumocystis Pneumonia Background P
Page 324 and 325:
Table 1. Standard and Alternative P
Page 326 and 327:
Progressive Multifocal Leukoencepha
Page 328 and 329:
Seborrheic Dermatitis Background Se
Page 330 and 331:
Sinusitis Background Sinusitis is d
Page 332 and 333:
Syphilis Background Syphilis is a s
Page 334 and 335:
Treponemal antibody tests (TP-PA [T
Page 336:
Some patients retain reactive (low-
Page 339 and 340:
6-106| Clinical Manual for Manageme
Page 341 and 342:
Page 343 and 344:
Page 345 and 346:
Page 347 and 348:
Page 349 and 350:
Page 351 and 352:
Page 353 and 354:
Page 355 and 356:
Page 357 and 358:
Pain Syndrome and Peripheral Neurop
Page 359 and 360:
Pharmacologic interventions The fol
Page 361 and 362:
Page 363 and 364:
Palliative Care and HIV Background
Page 365 and 366:
GASTROINTESTINAL Nausea, vomiting
Page 367:
Advance Care Planning Advance care
Page 370 and 371:
Page 373 and 374:
Depression Background Major depress
Page 375 and 376:
of symptoms. The risk of recurrence
Page 377 and 378:
Panic Disorder Background Panic dis
Page 379:
♦ If benzodiazepines are used, th
Page 382 and 383:
Page 384 and 385:
Page 386 and 387:
Page 388 and 389:
Page 390 and 391:
Page 392 and 393:
Page 395 and 396:
Sulfa Desensitization Background Tr
Page 397 and 398:
Patient Education Background It has
Page 399 and 400:
Web-Based Resources Background The
show all

Clinical Manual for Management of the HIV-Infected ... - myCME.com

Create successful ePaper yourself

Delete template?

Save as template?